Answers are grounded in this paper and cite their sources.
To systematically study the pharmacodynamics of a CNS drug early in the development process, we developed and validated a battery of drug-sensitive CNS tests, which we call NeuroCart. Using this test battery, data-intensive phase 1 studies in healthy subjects can be performed to demonstrate the specific, time- and dose-dependent, neurophysiological and/or neuropsychological effects of a compound, thereby confirming whether the test compound reaches its intended target in the CNS - or does not reach its intended target. We use this test battery to demonstrate that a compound passes the blood-brain barrier.
No takes yet. Share an insight, caveat, or question.
Groeneveld et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: